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Background: Afatinib is an oral irreversible ErbB family blocker that targets epidermal growth factor receptor
(EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and HER4 (ErbB4) and is approved for the
first-line treatment of advanced non–small cell lung cancer (NSCLC) with certain sensitizing EGFR mutations. As
anti-HER2 therapies have been associated with cardiac dysfunction, we report cardiac safety data for afatinib.
Methods: Cardiac data were analyzed from phase III trials of afatinib 40 mg in treatment-naive patients with EGFR
mutation–positive NSCLC (LUX-Lung 3 [LL3]; n = 229 afatinib, n = 111 chemotherapy) and afatinib 50 mg in EGFR
tyrosine kinase inhibitor–pretreated NSCLC patients (LUX-Lung 1 [LL1]; n = 390 afatinib, n = 195 placebo). Additional
pooled data from 49 trials (n = 3865 afatinib-treated patients) is reported. Cardiac failure adverse events (CF-AEs),
including symptomatic cardiac failure and depressed left ventricular ejection fraction (LVEF), were analyzed.
Results: Time at risk–adjusted CF-AE rates (events/100 patient-years) were similar for afatinib versus placebo in LL1
(2.40 vs 2.23) and versus chemotherapy in LL3 (2.28 vs 2.92); the pooled afatinib CF-AE rate (2.88) was consistent
with that for both trials. The frequency of clinically significant LVEF reductions was higher for chemotherapy in LL3
(2/15 [13.3 %], afatinib 13/208 [6.3 %]; p = 0.267) and similar to placebo in LL1 (5/122 [4.1 %], afatinib 14/304 [4.6 %];
p = 1.000).
Conclusion: Afatinib was not associated with cardiac failure or LVEF reductions in the afatinib clinical trial program.
Keywords: Afatinib, Cardiac safety, Non–small cell lung cancer, Tyrosine kinase inhibitorBackground
Afatinib is an oral, irreversible ErbB family blocker that
targets the epidermal growth factor receptor (EGFR/
ErbB1), human epidermal growth factor receptor 2
(HER2/ErbB2), and HER4 (ErbB4) [1, 2], which results
in the inhibition of ErbB3/HER3 phosphorylation [3].
This agent was approved by the US Food and Drug Ad-
ministration (FDA) in July 2013 for the first-line treat-
ment of metastatic non–small cell lung cancer (NSCLC)
in patients whose disease harbors common EGFR muta-
tions, namely exon 19 deletions (Del19) or exon 21* Correspondence: mewer@mdanderson.org
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test [4]. The first-line, phase III LUX-Lung 3 (LL3) trial
in metastatic EGFR mutation–positive NSCLC had doc-
umented a significant improvement in the primary
endpoint of progression-free survival (PFS) with afatinib
40 mg/day versus pemetrexed/cisplatin (11.1 vs
6.9 months; hazard ratio [HR], 0.58; p = 0.001) for all pa-
tients with EGFR mutations [5]. A larger median PFS
difference was noted for patients with common muta-
tions (13.6 months for afatinib vs 6.9 months for chemo-
therapy; HR, 0.47; p <0.001) [5, 6]. The LUX-Lung 1
(LL1) trial was a phase IIb/III study in patients with
chemotherapy- and EGFR tyrosine kinase inhibitor
(TKI)–progressive NSCLC, in which afatinib 50 mg/day
prolonged PFS versus placebo (3.3 vs 1.1 months; HR,
0.38; p <0.0001), but there was no corresponding im-
provement in the primary endpoint of overall survival
(OS; 10.8 vs 12.0 months; HR, 1.08; p = 0.74) [7]. First-
line afatinib significantly prolonged OS for patients withdistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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and LUX-Lung 6 (HR, 0.54; p = 0.0015 and HR, 0.64;
p = 0.023, respectively) [8]. The approved administra-
tion of afatinib is at the 40-mg dose level, to be given
orally once daily [4].
The HER2 pathway is known to play a role in normal
cardiac function [9]. HER2 is expressed in the heart, and
preclinical studies suggest that HER2 downstream path-
ways are important for cardiomyocyte survival [10].
Therefore, cardiotoxicity is an established safety concern
with the use of anticancer agents designed to target this
particular pathway, including the anti-HER2 monoclonal
antibody trastuzumab [11, 12] and the anti-HER2/EGFR
TKI lapatinib [13]. The cardiac adverse event (AE) pro-
file of molecularly targeted agents, including the afore-
mentioned anti-HER2 therapies and multitargeted small-
molecule TKIs, such as sunitinib, primarily consists of
symptomatic or asymptomatic declines in left ventricular
ejection fraction (LVEF) or alterations in blood pressure,
with prolongation of the corrected QT interval and
cardiac dysrhythmias as additional risks [14–17]. Car-
diac AEs reported with these newer agents are typic-
ally low-grade and reversible, including LVEF
reductions [18, 19] and blood pressure elevations with or
without secondary or end-organ involvement [17, 20].
Although trastuzumab- and TKI-attributable high-
grade cardiac AEs and cardiovascular mortality are
rare, concerns regarding the inherent propensity for
cardiovascular AEs have resulted in widespread moni-
toring and assessment of multiple cardiac parameters
in patients receiving these agents. At the same time,
however, assessing their true clinical impact has been
problematic. Unlike the anthracyclines, for which car-
diotoxicity is cumulative and dose related [21], car-
diac AEs associated with targeted therapies have been
far less predictable, have generally been reversible,
and have not precluded reintroduction of these agents
once the initial cardiac event has been controlled
[18–20]. Given the potential for cardiotoxicity with
HER2 inhibitors and the known activity of afatinib
against several ErbB family members, including HER2,
it is important to establish the cardiovascular AE pro-
file for afatinib as part of the clinical development
process.
A phase II trial of afatinib utilized electrocardiograms
(ECGs) to assess possible QTcF (QT interval corrected by
the Fridericia formula) effects and found no afatinib effect
on cardiac repolarization [22]. The analyses reported
herein were conducted to further characterize the cardiac
safety of afatinib, based on cardiac failure AEs (CF-AEs),
including symptomatic cardiac failure and LVEF reduc-
tions, reported from LL1 and LL3, as well as patient infor-
mation available from a large number of additional trials
that was derived from the broader clinical databases.Patients and methods
Study design, patients, and treatment
The study designs of LL1 (phase IIb/III) and LL3 (phase
III), both conducted in patients with stage IIIB/IV
adenocarcinoma of the lung, are described in detail in
their primary publications [5, 7]. In brief, in LL3, EGFR
TKI–naive patients with NSCLC and a documented
EGFR mutation were randomly assigned in a 2:1 ratio to
receive either afatinib 40 mg (229 patients) or chemo-
therapy with pemetrexed/cisplatin (111 patients) [5].
LL1 was conducted in EGFR TKI– and chemotherapy-
pretreated (up to 2 lines of chemotherapy) patients, who
were randomly assigned 2:1 to receive afatinib 50 mg/
day (390 patients) or placebo (195 patients) [7]. In
addition to the afatinib-treated patients from LL3 and
LL1 (n = 619), 3246 additional patients from all 47 com-
pleted, Boehringer Ingelheim–sponsored, phase I-III
clinical trials of afatinib, as well as from reported clinical
experience, were included in the pooled analysis. No tri-
als were excluded except for 1 blinded clinical trial of
afatinib in head and neck cancer that included only 3
patients at the time of the data cut. Overall, these trials
provided a combined cohort of 3865 patients treated
with afatinib, as monotherapy or as a component of a
combination regimen. This pooled data analysis set is a
heterogeneous population in terms of tumor type, prior
therapy, and afatinib dose and treatment.
When feasible, LVEF was assessed at baseline, every
12 weeks, and at the end of treatment. In all trials, AEs
were categorized and graded using National Cancer In-
stitute Common Terminology Criteria for Adverse
Events (NCI-CTCAE) version 3.0 [5, 7].
All studies were conducted in accordance with the
Declaration of Helsinki and guidelines on Good Clinical
Practice, and the protocols were approved by local ethics
committees at each participating center.
Data analysis
The endpoints of interest for this secondary analysis
were cardiac failure–related AEs and clinically signifi-
cant LVEF reductions, per multigated acquisition
(MUGA) scan or echocardiogram (ECHO). The Stan-
dardized MedDRA Query (SMQ) of “Cardiac Failure”
was utilized to identify CF-AEs (eg, acute left ventricular
failure, high-output cardiac failure, left ventricular fail-
ure) that were reported during the routine AE surveil-
lance of the trials. The SMQ was modified by removing
preferred terms considered non-specific (eg, edema) that
are common in the target population. Time at risk
(TAR)–adjusted CF-AE rates were used to compare
treatment arms in LL1 and LL3 due to large differences
in treatment exposures. TAR-adjusted CF-AE rates were
calculated as events per 100 patient-years, with the treat-
ment groups being compared using proportional hazards
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examined using the following criteria: LVEF <50 and
≥10 % decrease from baseline or LVEF ≥50 and ≥15 %
decrease from baseline, with partial recovery defined as
an increase in ejection fraction of ≥10 percentage points
from the nadir to a level ≤5 percentage points below
baseline, and full recovery defined as recovery to
within 5 percentage points of baseline. The frequency
of clinically significant LVEF reductions in the 2 treat-
ment arms of LL3 and LL1 were compared using 2 ×




The 229 patients who received afatinib 40 mg/day had a
mean treatment duration of 11.5 months, during which
5 patients had CF-AEs (n = 4; 1.7 %) or an LVEF reduc-
tion (n = 1; 0.4 %). The comparator group of 111 patients
treated with chemotherapy had a substantially shorter
mean treatment duration of 3.7 months, during which 1
CF-AE (0.9 %) and no LVEF declines were reported. The
TAR-adjusted CF-AE rates (events per 100 patient-years)
were similar for afatinib versus chemotherapy (2.28 vs
2.92; Table 1). There was 1 grade ≥3 CF-AE, which was
in the chemotherapy group; all other CF-AEs in both
arms were of grade 1 or 2.
Six CF-AEs were noted in 5 afatinib-treated patients,
all of which were associated with a transient decrease in
LVEF, and the LVEF recovered toward baseline in 4 pa-
tients despite continuation of afatinib therapy; all events
were non-serious and low grade (grade ≤2), and 3 events
were considered related to study drug (2 cases of dia-
stolic dysfunction and 1 case of left ventricular dysfunc-
tion). One patient had grade 2 left ventricular
dysfunction 567 days after starting afatinib treatment,Table 1 TAR–adjusted CF-AE rates in LL3, LL1, and a pooled analysis
LL3
TAR (mo)
TAR-adjusted CF-AE rate (events/100 patient-years)
HR (95 % CI)
LL1
TAR (mo)
TAR-adjusted CF-AE rate (events/100 patient-years)
HR (95 % CI)
Pooled
TAR (mo)
TAR-adjusted CF-AE rate (events/100 patient-years)
TAR time at risk, CF-AE cardiac failure adverse event, LL3 LUX-Lung 3, LL1 LUX-Lungwith a MUGA scan demonstrating LVEF reduction from
65 % at baseline to 47 % at this time point. Afatinib
treatment was discontinued 1 month later, and a follow-
up MUGA scan after 1 month showed an LVEF increase
to 56 %. Of note, 4 of the 5 patients had multiple cardiac
baseline conditions, which included coronary artery dis-
ease, hypertension, hypercholesterolemia, tricuspid re-
gurgitation, mitral regurgitation, pericardial effusion,
aortic valve sclerosis, and diastolic dysfunction.
The mean percent change from baseline to last LVEF
measurement was similar for the 2 treatment groups:
−1.06 % for chemotherapy and +2.17 % for afatinib
(Table 2 and Fig. 1a). Of note, only 15 patients in the
chemotherapy group had a follow-up LVEF measure-
ment, compared with 208 patients in the afatinib group.
Based on the criteria for defining clinically relevant
LVEF reductions, clinically significant LVEF reduction
occurred in 13 of 208 (6.3 %) patients in the afatinib 40-
mg group and 2/15 (13.3 %) patients in the chemother-
apy group, but the rates were not statistically significant
between the 2 groups (p = 0.267). LVEF data are summa-
rized in Table 2 and further summarized for the 13
afatinib-treated patients with clinically significant LVEF
reductions in Fig. 2.
LL1
For afatinib 50 mg/day, during a mean treatment duration
of 5.1 months, 4 of 390 patients (1.0 %) had a CF-AE.
Three of 4 events were assessed by the investigator as un-
related to afatinib, with alternative etiologies specified as
follows: grade 3 acute left ventricular failure (secondary to
a hypertensive crisis), grade 4 cardiac failure (concurrent
pneumonia), and grade 5 cardiac failure attributed to dis-
ease progression. The remaining CF-AE in the afatinib
group was a fatal acute left ventricular failure, assessed by



















1, HR hazard ratio, CI confidence interval
Table 2 Descriptive statistics for LVEF by treatmenta




Baseline LVEF, mean (SD) 66.0 (6.90) 66.60 (8.0)
Minimum LVEF during treatment, mean (SD) 62.63 (6.33) 68.87 (10.59)
% change from baseline to minimum, mean (SD) −4.90 (9.95) −1.06 (15.30)
Last LVEF during treatment, mean (SD) 67.30 (7.10) 68.90 (10.60)
% change from baseline to last, mean (SD) 2.17 (11.41) −1.06 (15.30)




Baseline LVEF, mean (SD) 64.90 (6.60) 63.90 (7.70)
Minimum LVEF during treatment, mean (SD) 62.35 (6.57) 63.73 (7.87)
% change from baseline to minimum, mean (SD) −3.41 (9.14) −0.88 (12.13)
Last LVEF during treatment, mean (SD) 64.20 (7.0) 64.40 (7.70)
% change from baseline to last, mean (SD) −0.39 (10.40) 0.27 (12.62)
LVEF left ventricular ejection fraction, LL3 LUX-Lung 3, SD standard deviation, LL1 LUX-Lung 1, ECHO echocardiogram
aIn LL3, 208 patients in the afatinib arm and 15 patients in the chemotherapy arm had a follow-up ECHO; in LL1, 304 patients in the afatinib arm and 122 patients
in the placebo arm had a follow-up ECHO
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ive pulmonary disease, emphysema, and chronic renal in-
sufficiency, who was hospitalized for a severe pulmonary
infection 4 weeks after starting afatinib. The next day, the
patient’s brain natriuretic peptide level was 10,167 pg/mL
(normal range, 0–336 pg/mL) and a clinical diagnosis of
acute left heart failure was made. Due to the patient’s
critical condition, diagnostic imaging, such as ECHO,
computed tomography scan, or chest x-ray, was not per-
formed. The patient died 4 days later, but no autopsy was
performed. The comparator group of 195 placebo recipi-
ents had a shorter mean treatment duration of 2.8 months,
during which 1 patient experienced cardiac failure (0.5 %).
There were no LVEF reductions reported as CF-AEs in ei-
ther group. The TAR-adjusted CF-AE rates were similar
for afatinib versus placebo (2.40 vs 2.23; Table 1). All the
CF-AEs in both groups were of grade ≥3 severity.
The mean percent change from baseline to last LVEF
measurement was comparable between groups (+0.27 %
placebo, −0.39 % afatinib; Table 2 and Fig. 1b). LVEF
data are summarized in Table 2 and further summarized
for the 14 afatinib-treated patients with clinically signifi-
cant LVEF reductions in Fig. 2. The frequency of clinic-
ally significant LVEF reductions for afatinib was similar
to placebo (14/304 [4.6 %] vs 5/122 [4.1 %]; p = 1.000).
There was no uniformity in the severity or the time to
onset of the LVEF reductions.
Pooled analysis
The 3865 patients who received afatinib (any dose) in
the pooled analysis had a mean duration of treatment of
5.7 months, during which 53 (1.4 %) patients developed
CF-AEs, the majority of which were grade ≤2. The TAR-adjusted CF-AE rate for this analysis population was
2.88 (Table 1), which is consistent with that seen with
afatinib in LL1 and LL3.
Discussion
The current analysis, capturing data from 2 controlled
phase III trials in NSCLC and a pooled analysis of 49 tri-
als conducted in various settings, supports low rates of
protocol-defined cardiac failure and clinically significant
LVEF reductions for the ErbB family blocker afatinib
that are comparable to those seen with the control treat-
ment arms. These results indicate that afatinib was not
associated with cardiac failure or clinically significant
LVEF reductions in this clinical trial program.
The established cardiotoxic potential of anti-HER2
therapeutics, such as trastuzumab [11, 12] and lapatinib
[13], as well as multitargeted TKIs, such as sunitinib
[20], has heightened the importance of evaluating the
cardiac safety profile of new targeted agents. In our ana-
lysis of afatinib reported here, to ensure that events indi-
cative of cardiac failure were not underestimated,
detailed analyses were designed to identify patients ex-
periencing cardiac failure based on a modification of the
MedDRA SMQ. In addition to cardiac failures, clinically
significant decreased LVEF readings via MUGA scan or
ECHO were also analyzed. In the reporting of LVEF re-
ductions, we opted for the application of conservative
criteria in defining clinically relevant events. Given the
likelihood of low frequencies of CF-AEs in the individual
trials in NSCLC, the overall cumulative pool of patients
(n = 3865) receiving any afatinib dose (as monotherapy
or in combination) was also analyzed to provide a larger
data set. Results for CF-AEs in this pooled analysis
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LL1 afatinib 50 mg LL1 placebo
Fig. 1 a Relative LVEF change from baseline in LL3. Although there was no global tendency to decline, there were 3 LVEF measurements in LL3
that were reduced from baseline, and there were no increases beyond the 700-day mark; these represent 3 distinct patients whose LVEF reductions
were not clinically significant (<10 % change from baseline) and were >50 % (the lowest LVEF was 61 %). b Relative LVEF change from baseline in
LL1. Although there was no global tendency to decline beyond the 700-day mark, 7 LVEF measurements were reduced or at neutral;
these 7 LVEF measurements were from 2 patients, and 1 patient had 3 measurements beyond day 700 (76.1 % on day 726, 76.9 % on
day 810, and 74.4 % on day 894) that were close to his baseline LVEF of 76.80 %. Another patient had 4 LVEF measurements beyond day
700 (76.3 % on day 735, 65.3 % on day 819, 56.5 % on day 903, and 55.0 % on day 945); disease progression was diagnosed around the time of
the final LVEF measurement. Abbreviations: LVEF, left ventricular ejection fraction; LL3, LUX-Lung 3; LL1, LUX-Lung 1
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and afatinib 50 mg in LL1. The frequency of CF-AEs in
the pooled analysis (1.4 %) was consistent with those for
the afatinib groups of the randomized controlled trials
(2.2 and 1.0 % in LL3 and LL1, respectively). With ex-
posure correction, the TAR-adjusted CF-AE rates were
likewise similar across the 3 groups of afatinib recipients:
2.88 in the pooled analysis versus 2.28 in LL3 and 2.40
in LL1 (Table 1). The incidence of CF-AEs with max-
imum CTCAE grade ≥3 in the pooled analysis (0.5 %)
was also within the range of that for the individual stud-
ies (0.0 and 1.0 % in LL3 and LL1, respectively).
Cardiovascular AEs related to anticancer treatment fall
into 2 distinct groups, generally referred to as Type I
(resulting in dose-related toxicity with destruction ofmyocytes) and Type II (for which myocyte dysfunction
without characteristic biopsy changes of myocyte de-
struction is a cardinal characteristic) [23]. Whereas
anthracyclines are known to produce Type I cardiotoxi-
city, trastuzumab, sunitinib, and other targeted agents
have been associated with Type II characteristics [24].
This is a clinically important distinction, as reintroduc-
tion and prolonged treatment with a Type II cardiotoxic
agent may be feasible in many cases [19]. Based on the
current analyses, afatinib does not appear to be associ-
ated with significant toxicity of either the Type I or Type
II form. Furthermore, preclinical and clinical data indi-
cate that afatinib does not have an effect on the QTc
interval [22]. The TAR-adjusted CF-AE rates for afatinib
did not vary significantly from those of the comparator
Adjudicated LVEF reductions
Full recovery, n = 6
Partial recovery, n = 2
No follow-up ECHO, n = 5
(final‡ LVEF measurement of >50%, n = 4;




Full recovery, n = 3
Partial recovery, n = 2
No follow-up ECHO, n = 9
(final‡ LVEF measurement of >50%, n = 7;
final‡ LVEF measurement of 46%, n = 1;




Fig. 2 Adjudicated LVEF reductions in the afatinib treatment arms of LL3 and LL1. Six of the 13 patients in the afatinib group for LL3 achieved a
full recovery, and 2 patients had a partial recovery. Follow-up ECHOs were not available for 5 patients, 4 of whom had a final LVEF measurement
of >50 %. The remaining patient had a final LVEF measurement of 47 %. Three of the 14 patients in the afatinib group for LL1 achieved a full recovery,
and 2 patients had a partial recovery. Follow-up ECHOs were not available for 9 patients, 7 of whom had a final LVEF measurement of
>50 %. One patient had disease progression and another patient experienced a final LVEF measurement of 46 %. Clinically significant LVEF
reductions were examined using established criteria: LVEF <50 and ≥10 % decrease from baseline or LVEF ≥50 and ≥15 % decrease from baseline.
Abbreviations: LVEF, left ventricular ejection fraction; LL3, LUX-Lung 3; LL1, LUX-Lung 1; ECHO, echocardiogram; SD, standard deviation. *Mean (SD)
percent change from baseline to minimum LVEF during treatment: −24.90 (4.86) for afatinib and −29.30 (0.99) for chemotherapy; mean (SD) percent
change from baseline to last LVEF during treatment: −13.95 (10.83) for afatinib and −29.30 (0.99) for chemotherapy. †Mean (SD) percent change from
baseline to minimum LVEF during treatment: −22.71 (3.33) for afatinib and −31.24 (7.94) for placebo; mean (SD) percent change from baseline to last
LVEF during treatment: −16.88 (8.45) for afatinib and −29.38 (11.52) for placebo. ‡Last reported LVEF measurement at database lock
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cardiotoxicity may be subclinical, with a large number of
patients required to detect small changes in cardiac pa-
rameters. No global subclinical cardiac changes were ob-
served in the current analysis, and there was a lack of
the characteristic clustering of cardiac events that has
been observed with known cardiotoxic agents [25].
Overall, in our evaluation of clinical trial data for afati-
nib, we identified no consistency in the nature of the
rare cardiovascular events and no evidence of direct or
primary cardiotoxicity. As with other agents, it is pos-
sible that afatinib may increase the likelihood of cardio-
vascular AEs in patients with limited reserves.
To date, no observational studies of baseline and on-
treatment rates of cardiac failure, specifically in patients
with EGFR mutation–positive NSCLC, have been pub-
lished. Prior studies in patients with NSCLC, without re-
gard to EGFR mutational status, had illustrated a high
rate of cardiovascular comorbidity in this population
(approximately 20 to 36 %, depending on the definitions
used) [26–29], as well as increased cardiac failure rates
in chemotherapy-treated versus -untreated patients
[30, 31]. In an analysis of the US SEER–Medicare data-
base that included 34,209 patients aged ≥65 years with
NSCLC (with follow-up through 2005), the risks of car-
diac failure and dysfunction were increased by 29 and
58 %, respectively, among patients receiving chemother-
apy (without concurrent radiation) relative to those re-
ceiving no chemotherapy or radiation [31]. Movingforward, additional analyses will be important for defin-
ing the cardiac risk specific to TKI therapy for EGFR
mutation–positive NSCLC.
We acknowledge that there are limitations inherent
to our analysis, which was of a post hoc nature and
based on data from clinical trials for which character-
izing the cardiac AE profile of afatinib was not the
primary objective. The treatment durations for afati-
nib were relatively short, measured in months rather
than years, with long-term safety assessments not cur-
rently possible for malignancies such as advanced
NSCLC (for which survival durations are still limited).
Follow-up ECHOs were performed in the majority of
patients, but in some clinical situations, it was deter-
mined by the investigator to be infeasible. In addition,
while the results of the pooled analysis were consist-
ent with those from the individual randomized trials
and provide some reassurance of a low cardiotoxic
potential for afatinib, the pooled data need to be
interpreted with a particularly high level of caution
given that LVEF monitoring was not consistent in
many of these trials and there was variability with re-
spect to other aspects of the study designs (including
the use of afatinib as monotherapy or as a component
of combination regimens). Furthermore, as patients
with baseline abnormal cardiac function were ex-
cluded from these trials, the effect of afatinib on this
population remains unknown. Clearly, additional stud-
ies are needed to further characterize the risk of TKI-
Ewer et al. Cardio-Oncology  (2015) 1:3 Page 7 of 8associated cardiotoxicity in patients with advanced
NSCLC and any potential cardiac AE profile nuances
for approved and investigational TKIs.
Conclusions
In conclusion, afatinib shows no evidence of direct or pri-
mary cardiac or cardiovascular toxicity. However, rare
events in vulnerable patients who have limited cardiac re-
serves could not be ruled out. Experience with agents that
manifest cardiovascular toxicity suggests that minimizing
cardiac stress prior to treatment may mitigate the expres-
sion of such events, and monitoring of patients deemed to
be at high risk of cardiovascular events is prudent.
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